1. Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer
- Author
-
Kyohei, Misawa, Hajime, Yasuda, Hironari, Matsuda, Munechika, Hara, Tomonori, Ochiai, Daisuke, Koyama, Hina, Takano, Noriaki, Iwao, and Michiaki, Koike
- Subjects
Lung Neoplasms ,Nivolumab ,Carcinoma, Non-Small-Cell Lung ,Programmed Cell Death 1 Receptor ,Internal Medicine ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,General Medicine - Abstract
Immune checkpoint inhibitors (ICIs) are widely used for the treatment of various cancers. However, paradoxical exacerbation of neoplasms, referred to as "hyperprogressive disease," has been reported in a proportion of patients treated with anti-programmed cell death-1 (PD-1)/PD-1 ligand (PD-L1) blockade. We herein report a case of acute adult T-cell leukemia (ATL) that developed shortly after the administration of nivolumab, a PD-1 inhibitor, to treat non-small-cell lung cancer. There were no signs of ATL before the administration of nivolumab, and seropositivity for human T-cell leukemia virus type-1 (HTLV-1) was confirmed after the development of acute ATL. We speculate that nivolumab likely contributed to the development of acute ATL.
- Published
- 2022
- Full Text
- View/download PDF